We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

c-Myc

c-Myc inhibitors act on the MYC transcription factor, a central regulator of cell growth and proliferation. The MYC proto-oncogene protein binds DNA only as a heterodimer with MYC-associated factor X (MAX), a partnership described in 1991. MYC-MAX dimers recognize E-box sequences and regulate genes for ribosome biogenesis, metabolism and cell cycle progression. Amplification, chromosomal translocation or upstream signaling deregulates MYC in many tumor types. Because MYC has no defined ligand-binding pocket, compounds approach it in different ways. 10058-F4, 10074-G5 and MYCi975 are small molecules that interfere with MYC-MAX dimerization. IZCZ-3 is described as a MYC transcription inhibitor that binds a G-quadruplex in the MYC promoter, and related ligands are listed under G-quadruplex.

1 Item

  • MDEG-541
    Cat. No.
    A23988

    MDEG-541

    MDEG-541 is a potent PROTAC degrader targeting the MYC-MAX complex, derived from the MYC-MAX dimerization inhibitor 10058-F4 (28RH) and thalidomide as the cereblon-recruiting ligand. It exhibits strong antiproliferative activity and reduces the expression of key oncogenic and regulatory proteins, including GSPT1, MYC, GSPT2, and PLK1. MDEG-541 is a valuable tool for studying MYC-driven cancers and targeted protein degradation strategies.

    In stock View Details
    5 mg
    $225.00
    10 mg
    $388.00
    All 4 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...